

Note: This document is a direct translation of the document released in Japanese. If there are any discrepancies between this document and the original Japanese version, the original Japanese version prevails.

Tokyo, June 4, 2025

FOR IMMEDIATE RELEASE

Our Relationship with Patent Infringement Lawsuit regarding Drug Use Patent Pertaining to Oral Antipruritus Medication “REMITCH®” announced by Toray Industries, Inc. on May 27, 2025

TORII PHARMACEUTICAL CO., LTD. (the “Company”) sells in Japan Oral Antipruritus Medication “REMITCH®” with respect to which Toray Industries, Inc. (Head Office: Chuo-ku, Tokyo, Representative Director and President: Mitsuo Ohya) (“Toray”) has obtained the approval for manufacture and sales.

Toray announced that Toray, based on its drug use patent (Patent No. 3531170, with patent term extension registration: Application Nos. 2017-700154 and 2017-700310) (the “Patent”; the extended patent term ended in November 2022) had filed a lawsuit (Lawsuit (*Ne*) No. 10037 of 2021) (the “Lawsuit”) in which Toray claimed against Sawai Pharmaceutical Co., Ltd. (“Sawai Pharmaceutical”) and Fuso Pharmaceutical Industries, Ltd. (“Fuso Pharmaceutical”) damages for the infringement of the Patent in connection with “Nalfurafine Hydrochloride OD Tablets 2.5 µg “SAWAI”” (the “Sawai Product”) and “Nalfurafine Hydrochloride OD Tablets 2.5 µg “FUSO”” (the “Fuso Product”), both of which are generic products, and that the Intellectual Property High Court handed down the ruling on May 27, 2025.

According to the Toray’s announcement, the ruling found that the manufacture and sales of the Sawai Product by Sawai Pharmaceutical and Fuso Product by Fuso Pharmaceutical during the extended term of the Patent constituted the infringement of the Patent and upheld Toray’s claim for damages, ordering Sawai Pharmaceutical to pay damages of 14,290,939,291 yen, and Fuso Pharmaceutical to pay damages of 7,472,878,838 yen, along with delay damages.

The Company agreed with Toray that the Company will receive from Toray half the amount of the damages and delay damages in the Lawsuit. However, at this point of time the ruling has not been finalized, the date the Company is entitled to the said damages and delay damages and the amount thereof have not been determined.

If the ruling has been finalized, it may affect the Company’s current net income. However, according to the announcement by Sawai Pharmaceutical and Fuso Pharmaceutical, the appeal against the ruling above is expected to be filed with the Supreme Court and, at this point of time, the amount and date of determination of the damages in the Lawsuit are uncertain. Accordingly, there is no change in the Company’s forecast for the fiscal year ending December 2025 (from January 1, 2025 to December 31, 2025) released by the Company on February 7, 2025. If the Company should disclose certain matters after the ruling of the Lawsuit has been finalized, the Company will promptly announce them.

End